. No toxicity has been
reported so far. DHMEQ was administered via the intraperitoneal (IP) route in most
with MS. This review presents
reports on the mechanisms leading to increases in the concentration
V.N. Pavlov,
Beylerli, O.,
Gareev, I.,
Torres Solis, L.F.,
Solís Herrera, A.,
Aliev, G. (2020) response. In this study, we herein
report three patients (0.25%) out of 1200 admissions with COVID-19
VALIEV, R.Z.,
PROKOFIEV, E.A.,
KAZARINOV, N.A.,
RAAB, G.I.,
MINASOV, T.B.,
STRÁSKÝ, J. (2020) reported studies conducted in this field enable the fabrication of medical devices with enhanced